对接受芳香化酶抑制剂治疗的绝经后乳腺癌女性进行骨质疏松症筛查：少即是多？ - Suppr | 超能文献

Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?

作者信息

Dhesy-Thind Sukhbinder K

出版信息

J Clin Oncol. 2012 May 1;30(13):1408-10. doi: 10.1200/JCO.2011.40.7015. Epub 2012 Feb 27.

DOI:10.1200/JCO.2011.40.7015

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?对接受芳香化酶抑制剂治疗的绝经后乳腺癌女性进行骨质疏松症筛查：少即是多？

J Clin Oncol. 2012 May 1;30(13):1408-10. doi: 10.1200/JCO.2011.40.7015. Epub 2012 Feb 27.

2

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.接受芳香化酶抑制剂治疗早期乳腺癌的绝经后妇女骨折预防的成本效益。

J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27.

3

Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.双能X线吸收法联合抗吸收治疗在接受芳香化酶抑制剂的澳大利亚乳腺癌女性中的成本效益分析

J Bone Miner Metab. 2017 Mar;35(2):199-208. doi: 10.1007/s00774-016-0742-2. Epub 2016 Mar 11.

4

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.乳腺癌治疗引起的骨质流失管理指南：英国专家组的共识立场声明

Cancer Treat Rev. 2008;34 Suppl 1:S3-18. doi: 10.1016/j.ctrv.2008.03.007. Epub 2008 Jun 2.

5

[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].[专家小组共识：芳香化酶抑制剂治疗后绝经后乳腺癌患者骨质流失和骨质疏松的预防、诊断与治疗]

Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):876-9.

6

Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.乳腺癌治疗相关的骨质疏松风险：获得预防性治疗的必要性。

Maturitas. 2009 Sep 20;64(1):1-3. doi: 10.1016/j.maturitas.2009.07.012. Epub 2009 Aug 25.

7

Breast cancer and osteoporosis.乳腺癌与骨质疏松症。

Curr Opin Endocrinol Diabetes Obes. 2013 Dec;20(6):532-8. doi: 10.1097/01.med.0000436195.10599.dd.

8

Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.肿瘤医学：唑来膦酸治疗乳腺癌所致骨丢失。

Nat Rev Clin Oncol. 2010 Apr;7(4):187-8. doi: 10.1038/nrclinonc.2010.19.

9

Pricey osteoporosis remedy doesn't beat older drugs.昂贵的骨质疏松症治疗药物并不比老药更有效。

Consum Rep. 2009 Aug;74(8):19.

10

Bone density in breast cancer: when to intervene?乳腺癌中的骨密度：何时进行干预？

J Clin Oncol. 2007 Aug 1;25(22):3194-7. doi: 10.1200/JCO.2007.12.3430. Epub 2007 Jun 18.

引用本文的文献

1

Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience.激素受体阳性早期乳腺癌患者对骨骼健康指南的依从性：瑞士队列研究的现状及临床影响

Bone Rep. 2021 Dec 11;16:101160. doi: 10.1016/j.bonr.2021.101160. eCollection 2022 Jun.

2

Cancer Treatment-Induced Bone Loss in women with breast cancer.乳腺癌女性患者的癌症治疗引起的骨质流失

Bonekey Rep. 2015 May 20;4:692. doi: 10.1038/bonekey.2015.60. eCollection 2015.

3

Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.乳腺癌和骨质疏松症 - 乳腺癌绝经后妇女癌症治疗相关骨丢失的管理。

Breast Care (Basel). 2014 Oct;9(5):312-7. doi: 10.1159/000368843.